35
and when the second dose of vaccination was longer than 5 months, it was found that the effectiveness
in the age group 12-15 years
- reduced to 38%
Age group 16-17 years old
- reduced to 46%
When the 3rd needle was injected
for the age group 16-17 years old
- Increased productivity from 46% to 86%.
In the case of effectiveness in preventing hospitalization
- 5-11 years, efficiency 74%
- 12-15 years, 92% effectiveness
- 16-17 years, 94% effectiveness
If the second dose of vaccination is longer than 5 months
age group 12-15 years
- The effectiveness was reduced to 73%.
age group 12-15 years
The effectiveness was reduced to 73%.
So it can be concluded that
- Two doses of vaccine in children 12-17 years old prevent less than 50% of moderate infection by 5 months.
- If the third booster was given 5 months following the second dose, in the 16-17 year age group, the efficacy increased to 86%.
- Effectiveness in preventing hospitalization For the two-dose vaccinations, they were at 92 and 94%, following five months they dropped to 73 and 88%, respectively.
That is, children aged 12-17 will need a third dose of Pfizer booster vaccination more than 5 months following the second dose has been given.
